For pioneering companies in emerging #biopharma fields like #genetherapy, fostering a collaborative environment and a culture that encourages new ideas, the right approach to taking risks, and new ways of collaborating is crucial. Hear from our Senior Vice President, Primary Focus Lead (Genetic Regulation), Richard Wilson, and Asset Lead, Gene Therapy, Jill Woloszynek, on the importance of corporate culture at Astellas.
关于我们
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina. Content is intended for a US audience.
- 网站
-
https://www.astellasgenetherapies.com
Astellas Gene Therapies的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- San Francisco，CA
- 类型
- 上市公司
- 领域
- gene therapy和biotechnology
地点
-
主要
获取路线
600 California St
US，CA，San Francisco，94108
Astellas Gene Therapies员工
动态
-
This #NationalFamilyCaregiversMonth, we’re celebrating the vital role of caregivers in our society. Hear from our Director, Patient Partnerships, Chelsea Moran, on how Astellas engages the caregiver community to increase support for caregivers worldwide.
-
-
#ICYMI yesterday, our Executive Director, Head of Medical Affairs, Established Markets, Dr. Rainel Sanchez-de la Rosa, M.D., Ph.D., moderated a keynote panel at the Festival of Biologics in Basel, where he led an engaging discussion about the accessibility of curative #genetherapies.?? ? #FestivalOfBiologics?
-
-
This week, members of our team will be presenting a poster on our #genetherapy work in X-linked myotubular myopathy (#XLMTM) at The World Muscle Society (WMS) Congress in Prague. We look forward to sharing more about our EXCEL study which aims to assess liver health by estimating the incidence & prevalence of cholestatic complications in #patients with XLMTM. #WMS2024
-
-
We’re proud to share that today, Astellas announced an exclusive option and license agreement with AviadoBio for AVB-101, an investigational, AAV-based #GeneTherapy in Phase 1/2 development for patients with frontotemporal #dementia with progranulin mutations (FTD-GRN). This partnership further supports our commitment to deliver transformative value for patients and we look forward to working with AviadoBio to help support the unmet need for treatment options for this neurodegenerative disease. Learn more here:? https://lnkd.in/gbeZGFRz
-
We’re looking forward to attending the Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa in Arizona! Learn more about the upcoming presentations from our Senior Vice President, Primary Focus Lead, Genetic Regulation, Richard Wilson, and Medical Head, Cell and Gene Therapy, Ha Tran, MD, MS below: #CGMesa24
In pioneering fields such as #CellandGeneTherapy, cross-industry collaboration and communication are essential for accelerating the delivery of potential transformative medicines to patients. At the upcoming Cell and Gene Meeting on the Mesa, October 7-9, Astellas speakers will be setting out our vision in cell and gene therapy, exploring how to navigate the evolving gene therapy landscape in Asia, and sharing updates on our work in diseases facing significant unmet medical needs, such as Friedreich ataxia (#FA). Our partnering teams will also be onsite, looking for like-minded innovators committed to bringing ground-breaking therapies to patients, faster. Get in touch if you’re attending: https://lnkd.in/gapkuMAZ #ScienceFirstForPatients #ChangingTomorrow #CGMesa24
-
-
On #InternationalAtaxiaAwarenessDay (IAAD), we shine a spotlight on #FriedreichAtaxia (FA) and the critical work being done to support this community. Hear from Christine Schlegel Brown, a champion for patient advocacy, on how she ensures the patient voice is central in developing #genetherapies at AGT. Join us in raising FA awareness and advocating for transformative treatments and patient care.
-
Myotonic dystrophy (#DM1) is caused by a genetic mutation preventing specific genes from functioning properly, impacting muscle systems throughout the body. People living with DM1 have a 50% chance of passing it on to their children. Early genetic testing and counseling can save lives – help raise awareness in the medical community by supporting #myotonicDystrophyAwareness Day & learn more below.
-
Astellas Gene Therapies recently participated at Friedreich's Ataxia Research Alliance (FARA)’s Research Reception in Illinois.?The meeting enabled us to hear directly from the patients and families affected by Friedreich Ataxia (FA) and share Astellas’ commitment to investigating potential gene therapies for people with cardiomyopathy from FA.?Our partnership with the FA community is building and growing as we continue to involve the patient voice in every step of drug development.
-